Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.

Kaukua JK, Pekkarinen TA, Rissanen AM.

Int J Obes Relat Metab Disord. 2004 Apr;28(4):600-5.

PMID:
14770192
2.

Pharmacological intervention: the antiobesity approach.

Rissanen A.

Eur J Clin Invest. 1998 Sep;28 Suppl 2:27-30. Review.

PMID:
9777325
3.

Sibutramine. A review of its contribution to the management of obesity.

McNeely W, Goa KL.

Drugs. 1998 Dec;56(6):1093-124. Review.

PMID:
9878996
4.

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.

García Díaz E, Martín Folgueras T.

Nutr Hosp. 2011 May-Jun;26(3):451-7. doi: 10.1590/S0212-16112011000300004. Review.

5.

New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.

Scheen AJ, Ernest P.

Diabetes Metab. 2002 Dec;28(6 Pt 1):437-45. Review.

6.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
7.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
8.

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.

Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J.

Arch Intern Med. 2004 Jul 12;164(13):1395-404. Review.

PMID:
15249348
9.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

10.

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.

Johansson K, Sundström J, Neovius K, Rössner S, Neovius M.

Obes Rev. 2010 Nov;11(11):777-91. doi: 10.1111/j.1467-789X.2009.00693.x. Review.

PMID:
20025693
11.

Obesity and type 2 diabetes: a conflict of interests?

Williams G.

Int J Obes Relat Metab Disord. 1999 Jun;23 Suppl 7:S2-4. Review.

PMID:
10455464
12.

Sibutramine--a review of clinical efficacy.

Lean ME.

Int J Obes Relat Metab Disord. 1997 Mar;21 Suppl 1:S30-6; discussion 37-9. Review.

PMID:
9130039
13.

The importance of obesity in diabetes and its treatment with sibutramine.

Van Gaal LF, Peiffer FW.

Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 4:S24-8. Review.

PMID:
11916103
14.

Metabolic benefits associated with sibutramine therapy.

Krejs GJ.

Int J Obes Relat Metab Disord. 2002 Dec;26 Suppl 4:S34-7. Review.

PMID:
12457298
15.

Obesity medications and the treatment of type 2 diabetes.

Greenway F.

Diabetes Technol Ther. 1999 Fall;1(3):277-87. Review.

PMID:
11475274
16.

Sibutramine: its mode of action and efficacy.

Finer N.

Int J Obes Relat Metab Disord. 2002 Dec;26 Suppl 4:S29-33. Review.

PMID:
12457297
17.

Sibutramine in overweight/obese hypertensive patients.

Sharma AM.

Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 4:S20-3. Review.

PMID:
11916102
18.

The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials.

Warkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS.

Obes Rev. 2014 Mar;15(3):169-82. doi: 10.1111/obr.12113. Epub 2013 Oct 3. Review.

PMID:
24118750
19.

When, for whom and how to use sibutramine?

Astrup A, Toubro S.

Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 4:S2-7. Review.

PMID:
11916101
20.

The role of sibutramine in weight management--towards a blueprint for a sibutramine weight management system.

James WP, Finer N.

Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 4:S34-8. Review.

PMID:
11916105
Items per page

Supplemental Content

Write to the Help Desk